Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
inotuzumab ozogamicin 0.9 MG Injection [Besponsa]
0.9 MG · Injection · injection
A form of inotuzumab ozogamicin →
inotuzumab ozogamicin 0.9 MG Injection [Besponsa] — CD22 (Clusters of Differentiation 22) inhibitors. Strength, form, class, interactions & more.
![inotuzumab ozogamicin 0.9 MG Injection [Besponsa]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cc7014b1-c775-411d-b374-8113248b4077&name=besponsa-01.jpg)
Active ingredient
Classification
Drug interactions
Concomitant use of BESPONSA with drugs that prolong the QT interval may increase the risk of QTc interval prolongation.
- majordrugs that prolong the QT interval — increased risk of clinically significant QTc interval prolongation
Real-world adverse events (FAERS)
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication